一位民主党资深议员承诺，将利用其党新获得的国会多数席位，对医疗保健行业发起攻势。
A top Democratic lawmaker is promising to target the healthcare industry with his party’s newly minted congressional majority.
医疗保健公司，包括大型保险商和药企，去年纷纷与唐纳德·特朗普总统政府达成协议，以规避监管行动和关税，当时环境极难预测。辉瑞公司首席执行官阿尔伯特·布尔拉周二在财报电话会上大肆宣扬这些制药协议，称其为投资者带来了稳定性。
Healthcare companies, including large insurers and drugmakers, scrambled to cut deals with President Donald Trump’s administration last year to avert regulatory action and tariffs in a highly unpredictable environment. Pfizer Chief Executive Officer Albert Bourla touted the pharma deals during an earnings call on Tuesday, lauding the stability they brought for investors.
俄勒冈州参议员罗恩·怀登将于明年一月民主党掌权后，出任实力强劲的参议院财政委员会主席。他在周三警告医疗行业高管将面临问责。民主党在国会制衡特朗普政府最直接的手段，将是举行听证会和发出传票进行监督的权力。
Oregon Senator Ron Wyden, who is poised for the top perch on the powerful Senate Finance Committee when Democrats take power in January, threatened accountability for health industry executives on Wednesday. Democrats’ most immediate tools to attack the Trump administration in Congress will be the ability to conduct oversight by calling hearings and issuing subpoenas.
怀登承诺，将要求“对于为榨取利润而拖延和拒绝提供医疗保健的保险公司”以及“对于在享受特朗普亲手送上的意外之财时却哄抬物价的制药公司首席执行官”进行问责。他批评特朗普政府与药企达成的药品定价协议过于隐秘，并补充说，在九月的一次听证会上，这些公司获得了“甜心关税协议并推高了股价”。过去一周，包括礼来公司、默克公司和百时美施贵宝公司在内的多家药企在季度财报中报告了创纪录的收入。
Wyden promised to demand accountability from “insurance companies that are delaying and denying healthcare to churn a profit” and “the pharmaceutical company CEOs that price gouge while enjoying Trump’s hand-delivered windfalls.”He criticized drug pricing deals that the Trump administration struck with drugmakers as too secretive, adding in a September hearing that companies got “sweetheart tariff deals and boosted stock prices.”Several drugmakers including Eli Lilly & Co., Merck & Co. and Bristol Myers Squibb Co. reported record revenue in quarterly earnings releases in the past week.
怀登承诺，将为终结“企业对国家医疗保健系统的垄断控制”奠定基础，同时扩大医疗保健覆盖面并降低成本。
Wyden promised to lay groundwork to end “the corporate chokehold on our nation’s healthcare system” as well as expand healthcare access to all and reduce its cost.
该议员团队已传阅政策议程，内容包括扩大医疗保险谈判药价的权力，以及针对健康保险商的商业行为。
The lawmaker’s team has circulated policy agendas that include expanding Medicare’s ability to negotiate drug prices and targeting health insurers’ business practices.
然而，即使在国会两院都拥有压倒性多数的情况下，在分裂政府下让立法签署成法也将十分困难。要推翻特朗普总统的任何否决，两院都需要三分之二多数。
Getting legislation signed into law in a divided government will be difficult, however, even with commanding majorities in both chambers of Congress. A two-thirds majority would be required in both chambers to overcome any veto from President Trump.
短期内，如果民主党推动撤销特朗普时代对医疗补助计划的削减以及对《平价医疗法案》计划补贴的削减，保险公司和医院可能在财务上受益。
In the short term, insurance companies and hospitals could benefit financially if Democrats push to roll back Trump-era cuts to Medicaid and subsidies for Affordable Care Act plans.
不过，彭博情报分析师杜安·赖特表示，选举结果对制药商、健康保险公司和医院构成的“近期风险有限”。他补充称，制药行业面临“最明确的长期下行风险”，因为民主党“总体上支持扩大医疗保险药品谈判，更快的资格门槛和更广泛的药品范围可能使更多品牌药收入面临风险，如果该党在2028年后实现统一执政的话。”
However, Bloomberg Intelligence analyst Duane Wright said that the election results pose “limited near-term risks for drugmakers, health insurers and hospitals.”He added the pharmaceutical industry faces “the clearest long-term downside” because Democrats “broadly favor expanding Medicare drug talks, with faster eligibility and a wider pool of drugs potentially putting more branded revenue at risk if the party achieves unified control after 2028.”